Automated HPLC-MS/MS assay for the simultaneous determination of ten plasma antibiotic concentrations.


Journal

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
ISSN: 1873-376X
Titre abrégé: J Chromatogr B Analyt Technol Biomed Life Sci
Pays: Netherlands
ID NLM: 101139554

Informations de publication

Date de publication:
15 Nov 2022
Historique:
received: 16 06 2022
revised: 13 09 2022
accepted: 03 10 2022
pubmed: 17 10 2022
medline: 9 11 2022
entrez: 16 10 2022
Statut: ppublish

Résumé

Therapeutic drug monitoring (TDM) of antibiotics (ATB) in patients with serious bacterial infections allows optimization of the efficacy of the treatment while reducing the risk of toxicity. Notably, early measurement of plasma beta-lactam concentration has been shown to be associated with reduced mortality in intensive care patients. In this context, a rapid, robust, and accurate assay method is essential for daily TDM. A fully automated procedure for quantification of the plasma concentrations of ten ATB was developed. The ATB were divided into two calibration pools, with Pool 1: aztreonam, ceftobiprole, cefoxitin, avibactam, tazobactam and Pool 2: metronidazole, ceftriaxone, daptomycin, ceftolozane, moxifloxacin. Sample preparation consisting of acetonitrile plasma protein precipitation and H20 dilution was applied to all analytes. This procedure was carried out by an automated sample preparation system directly coupled to a liquid chromatography-tandem mass spectrometry (LC-MS/MS) system. Since the instrument extracts sample n while sample n-1 is in the LC-MS/MS system, the delay between obtaining the results for two samples corresponds to the analytical run time, which is less than 7 min. The method was validated according to the Food and Drug Administration guidelines. The method was sensitive (lower limit of quantification 0.1-1 mg/L, depending on the ATB), accurate (intra/inter-assay bias -14.8 to 14.2 %) and precise (intra/inter-assay CVs 1.27 to 16.3 %). Application of the TDM assay was illustrated by the report of an intensive care patient treated with the ceftazidime/aztreonam/avibactam combination. Four assays were performed in 8 days with results returned within 24 h to quickly manage the dose regimen in this patient. An automated, simple, rapid, robust LC-MS/MS analysis was developed and validated for the simultaneous quantification of plasma concentrations of 10 ATB and was applied with success to perform TDM. This method provides a shorter turnaround time than classic sample batch-based analytical methods.

Identifiants

pubmed: 36244237
pii: S1570-0232(22)00400-7
doi: 10.1016/j.jchromb.2022.123496
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
avibactam 7352665165
Aztreonam G2B4VE5GH8

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

123496

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Sophie Magréault (S)

Unité Fonctionnelle de Pharmacologie, AP-HP, Groupe Hospitalier Paris Seine Saint-Denis, F-93140 Bondy, France; Université Sorbonne Paris Nord and Université Paris Cité, Inserm, IAME, F-93000 Bobigny, France. Electronic address: sophie.magreault@aphp.fr.

Françoise Jaureguy (F)

Université Sorbonne Paris Nord and Université Paris Cité, Inserm, IAME, F-93000 Bobigny, France; Service de Microbiologie Clinique, AP-HP, Groupe Hospitalier Paris Seine Saint-Denis, F-93000 Bobigny, France.

Jean-Ralph Zahar (JR)

Université Sorbonne Paris Nord and Université Paris Cité, Inserm, IAME, F-93000 Bobigny, France; Service de Microbiologie Clinique et Unité de Contrôle et de Prévention du risque Infectieux, AP-HP, Groupe Hospitalier Paris Seine Saint-Denis, F-93000 Bobigny, France.

Frédéric Méchaï (F)

Université Sorbonne Paris Nord and Université Paris Cité, Inserm, IAME, F-93000 Bobigny, France; Service des Maladies Infectieuses et Tropicales, AP-HP, Groupe Hospitalier Paris Seine Saint-Denis, F-93000 Bobigny, France.

Doriane Toinon (D)

Shimadzu Corporation, Kyoto, Japan.

Yves Cohen (Y)

Service de Réanimation médico-chirurgicale, AP-HP, Groupe Hospitalier Paris Seine Saint-Denis, F-93000 Bobigny, France; Université Sorbonne Paris Nord, F-93000 Bobigny, France.

Etienne Carbonnelle (E)

Université Sorbonne Paris Nord and Université Paris Cité, Inserm, IAME, F-93000 Bobigny, France; Service de Microbiologie Clinique, AP-HP, Groupe Hospitalier Paris Seine Saint-Denis, F-93000 Bobigny, France.

Vincent Jullien (V)

Unité Fonctionnelle de Pharmacologie, AP-HP, Groupe Hospitalier Paris Seine Saint-Denis, F-93140 Bondy, France; Université Sorbonne Paris Nord, F-93000 Bobigny, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH